ProPharma Partners and Biolink International form Partnership
Pleasanton, CA (Dec. 22, 2005) -
We are pleased to announce the formation of the recent partnership between ProPharma Partners and Biolink International.
ProPharma Partners, with offices in London and the San Francisco Bay area in California, and Biolink International, Inc., with offices in Tokyo and Pennsylvania, provide extensive business development and strategic advisory expertise at the local, regional and/or global level in the major pharmaceutical markets of Japan & Asia, Europe and North America.
This new partnership expands the breadth of services and global reach ProPharma Partners and Biolink International are able to provide to the pharmaceutical and biotechnology industries. Client companies who engage ProPharma or Biolink can expand access to the expertise and contacts of ProPharma and Biolink globally.
ProPharma Partners and Biolink International have an extensive record of successfully providing a range of services which include:
About BioLink International
Biolink International, Inc. is a Japan-based consulting firm that provides specialized services and solutions to pharmaceutical firms, bio-venture firms in the pre- and post-IPO stages, and technology-based firms that aim to expand strategic partnerships and alliances in Japan for business growth and global coverage.
Biolink International, Inc. offers services the following healthcare related areas:
About ProPharma Partners
ProPharma Partners Inc. provides extensive business consulting and drug development expertise to early stage and established biopharmaceutical companies. ProPharma Partners specializes in assisting companies plan and implement strategic, business and product development initiatives. With offices in Hayward, California, London, Tokyo and Taipei, ProPharma Partners has the expertise and the capability to facilitate technology and product development transactions among US, European and Japanese companies.
The global reach of ProPharma Partners provides client companies a truly international source of expertise to assist in navigating through cultural, legal and language differences in order to achieve their international pharmaceutical and business development objectives. For further information, visit www.propharmaipartners.com.
There are forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continue," "anticipates," "intends," "expects," and similar expressions. Examples include statements above (i) regarding the potential benefits of extending the duration of action of PGN0052, (ii) anticipating the optimization of the pharmacokinetic properties of PGN0052 through the application of PEG technology, (iii) regarding the potential receipt of milestone and royalty payments, (iv) regarding the potential formation of a joint development and commercialization agreement, (v) contemplating the potential usefulness of PGN0052 in cystic fibrosis and other indications and (vi) predicting the timing of Phase 2 study results. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments discussed above. Such factors include the risks that the application of PEG technology may not improve the pharmacokinetic properties of PGN0052, that the Phase 2 study may be delayed or that PGN0052 may not emerge successfully from it, that PGN0052 may not receive regulatory approval from the FDA, and that Pharmagene and/or Enzon may not be able to successfully commercialize PGN0052 if it does receive regulatory approval from the FDA, as well as those described in Enzon's Form 10-K and Forms 10-Q on file with the SEC, such as, Enzon's ability to sustain profitability, and positive cash flow; market acceptance of and continuing demand for Enzon's products; and the impact of competitive products and pricing. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. All information in this press release is as of September 16, 2004 and the Company undertakes no duty to update this information.
|+1 510 681 4445|